|
1
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001.PubMed/NCBI
|
|
2
|
Okada M: Subtyping lung adenocarcinoma
according to the novel 2011 IASLC/ATS/ERS classification:
correlation with patient prognosis. Thorac Surg Clin. 23:179–186.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raparia K, Villa C, DeCamp MM, Patel JD
and Mehta MP: Molecular profiling in non-small cell lung cancer: a
step toward personalized medicine. Arch Pathol Lab Med.
137:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nuijten MJ, Aultman R, de Carpeño JC, et
al: An indirect comparison of the efficacy of bevacizumab plus
carboplatin and paclitaxel versus pemetrexed with cisplatin in
patients with advanced or recurrent non-squamous adenocarcinoma
non-small cell lung cancer. Curr Med Res Opin. 27:2193–2201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dinglin XX, Huang Y, Liu H, et al:
Pemetrexed and cisplatin combination with concurrent whole brain
radiotherapy in patients with brain metastases of lung
adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol.
112:461–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tímár J: Role of contemporary pathological
diagnostics in the personalized treatment of cancer. Magy Onkol.
57:26–32. 2013.(In Hungarian).
|
|
7
|
Park SY, Lee JG, Kim J, et al:
Preoperative serum CYFRA 21-1 level as a prognostic factor in
surgically treated adenocarcinoma of lung. Lung Cancer. 79:156–160.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ono A, Takahashi T, Mori K, et al:
Prognostic impact of serum CYFRA 21-1 in patients with advanced
lung adenocarcinoma: a retrospective study. BMC Cancer. 13:3542013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeuchi S, Nonaka M, Kadokura M and
Takaba T: Prognostic significance of serum squamous cell carcinoma
antigen in surgically treated lung cancer. Ann Thorac Cardiovasc
Surg. 9:98–104. 2003.PubMed/NCBI
|
|
10
|
Hatzakis KD, Froudarakis ME, Bouros D, et
al: Prognostic value of serum tumor markers in patients with lung
cancer. Respiration. 69:25–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bréchot JM, Chevret S, Nataf J, et al:
Diagnostic and prognostic value of Cyfra 21-1 compared with other
tumour markers in patients with non-small cell lung cancer: a
prospective study of 116 patients. Eur J Cancer. 33:385–391.
1997.PubMed/NCBI
|
|
12
|
Rubins JB, Dunitz J, Rubins HB, et al:
Serum carcinoembryonic antigen as an adjunct to preoperative
staging of lung cancer. J Thorac Cardiovasc Surg. 116:412–416.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seregni E, Foa P, Bogni A, et al:
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in
non-small cell lung cancer (NSCLC). Oncol Rep. 3:95–101.
1996.PubMed/NCBI
|
|
14
|
Diez M, Torres A, Pollán M, et al:
Prognostic significance of serum CA 125 antigen assay in patients
with non-small cell lung cancer. Cancer. 73:1368–1376. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riesener KP and Schumpelick V: Ultrasound
diagnosis in abdominal trauma - how much experience does the
surgeon need to perform ultrasonic diagnosis? Langenbecks Arch
Chir. 377:205–206. 1992.(In German).
|
|
16
|
Cristofori R, Aimo G, Mengozzi G, et al:
Tumor markers kinetic in malignant lung neoplasms. J Cardiovasc
Surg (Torino). 40:299–305. 1999.PubMed/NCBI
|
|
17
|
Yoshimasu T, Miyoshi S, Maebeya S, et al:
Analysis of the early postoperative serum carcinoembryonic antigen
time-course as a prognostic tool for bronchogenic carcinoma.
Cancer. 79:1533–1540. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cammisotto PG, Bukowiecki LJ, Deshaies Y
and Bendayan M: Leptin biosynthetic pathway in white adipocytes.
Biochem Cell Biol. 84:207–214. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tas F, Duranyildiz D, Argon A, et al:
Serum levels of leptin and proinflammatory cytokines in
advanced-stage non-small cell lung cancer. Med Oncol. 22:353–358.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ribeiro R, Araujo A, Lopes C and Medeiros
R: Immunoinflammatory mechanisms in lung cancer development: is
leptin a mediator? J Thorac Oncol. 2:105–108. 2007.PubMed/NCBI
|
|
21
|
Karapanagiotou EM, Tsochatzis EA, Dilana
KD, et al: The significance of leptin, adiponectin, and resistin
serum levels in non-small cell lung cancer (NSCLC). Lung Cancer.
61:391–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao X, Huang K, Zhu Z, Chen S and Hu R:
Correlation between expression of leptin and clinicopathological
features and prognosis in patients with gastric cancer. J
Gastroenterol Hepatol. 22:1317–1321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang SN, Yeh YT, Yang SF, Chai CY and Lee
KT: Potential role of leptin expression in hepatocellular
carcinoma. J Clin Pathol. 59:930–934. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guadagni F, Roselli M, Martini F, et al:
Prognostic significance of serum adipokine levels in colorectal
cancer patients. Anticancer Res. 29:3321–3327. 2009.PubMed/NCBI
|
|
25
|
Sato Y, Watanabe H, Sone M, et al; Japan
Intervention Radiology in Oncology Study Group-JIVROSG. Tumor
response evaluation criteria for HCC (hepatocellular carcinoma)
treated using TACE (transcatheter arterial chemoembolization):
RECIST (response evaluation criteria in solid tumors) version 1.1
and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci.
118:16–22. 2013. View Article : Google Scholar
|
|
26
|
Lin J, Gao XN, Yan GT, et al: Endogenous
leptin fluctuates in hepatic ischemia/reperfusion injury and
represents a potential therapeutic target. World J Gastroenterol.
16:5424–5434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fleeman N, Bagust A, McLeod C, et al:
Pemetrexed for the first-line treatment of locally advanced or
metastatic non-small cell lung cancer. Health Technol Assess.
14(Suppl 1): 47–53. 2010.
|
|
28
|
Lord RV, Brabender J, Gandara D, et al:
Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung
cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
29
|
Besse B, Olaussen KA and Soria JC: ERCC1
and RRM1: ready for prime time? J Clin Oncol. 31:1050–1060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pillai RN, Brodie SA, Sica GL, et al: CHFR
protein expression predicts outcomes to taxane-based first line
therapy in metastatic NSCLC. Clin Cancer Res. 19:1603–1611. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kerenidi T, Lada M, Tsaroucha A, et al:
Clinical significance of serum adipokines levels in lung cancer.
Med Oncol. 30:5072013. View Article : Google Scholar : PubMed/NCBI
|
